The performance of companies tied to iconic drugs like Viagra presents a complex investment landscape . While the initial boom of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the loss of exclusivity in key regions has introduced significant volatility. Investors are now assessing the impact of generic compe